Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy

Bibliography

• BELLM LA, EPSTEIN JB, ROSE-PED A, MARTIN P, FUCHS HJ: Patient reports of complications of bone marrow transplantation. Supp. Care Cancer (2000) 8:33-39.
   PubMed Web of Science ®Google Scholar
• ROSE-PED AM, BELLM LA, EPSTEIN JB, TROTTI A, GWEDE C, FUCHS HJ: Complications of radiation therapy for head and neck cancers: the patient’s perspective. Cancer Nurs. (2002) 25:461-467.
   PubMed Web of Science ®Google Scholar
• MCGUIRE DB, YAEGER KA, DUDLEY WN et al.: Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study. Cancer Nurs. (1998) 21:385-393.
   PubMed Web of Science ®Google Scholar
• DUNBAR PJ, BUCKLEY P, GAVRIN JR, SANDERS JE, CHAPMAN CR: Use of patient-controlled analgesia for pain control for children receiving bone marrow transplant. J. Pain Symptom Manage. (1995) 10(8):604-611.
   PubMed Web of Science ®Google Scholar
• PERCH SJ, MACHTAY M, MARKIEWICZ DA, KLIGERMAN MM: Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx. Radiology (1995) 197(3):863-866.
   PubMed Web of Science ®Google Scholar
• DUNCAN M, GRANT G: Oral and intestinal mucositis-causes and possible treatments. Alimentary Pharmacol. Therapeutics (2003) 18:853-874.
   PubMed Web of Science ®Google Scholar
• SYRJALA KL, CHAPKO ME: Evidence for a biopsychosocial model of cancer treatment-related pain. Pain (1995) 61(1):69-79.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, STEWART KH: Radiation therapy and pain in patients with head and neck cancer. Eur. J. Cancer B. Oral Oncol. (1993) 29B(3):191-199.
   PubMed Web of Science ®Google Scholar
• SONIS ST: A biological approach to mucositis. J. Support Oncol. (2004) 2(1):21-32.
   PubMedGoogle Scholar
• HANDSCHEL J, PROTT FJ, MEYER U, KLEINHEINZ J, WALDE M, JOOS U: Prospective study of the pathology of radiation-induced mucositis. Mund-Kiefer- Gesichtschirurgie (1998) 2:131-135.
   PubMedGoogle Scholar
• EPSTEIN JB, EMERTON S, GUGLIETTA A, LE N: Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol. (1997) 33:359-363.
   PubMed Web of Science ®Google Scholar
• GORDON B, SPADINGER A, HODGES E, RUBY E, STAMLEY R, COCCIA P: Effect of granulocyte-macrophage colony stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J. Clin. Oncol. (1994) 12:1917-1922.
   PubMed Web of Science ®Google Scholar
• REYNOSO EE, CALDERON E, MIRANDA E: GM-CSF mouthwashes to attenuate severe mucositis after high dose chemotherapy and allergenic bone marrow transplantation (BMT) or autologous peripheral blood stem cell transplantation (APBSCT). Annals Oncol. (1994) 5(Suppl. 8):1062.
   Google Scholar
• RAPOPORT AP, MILLER-WATELET LF, LINDER T et al.: Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J. Clin. Oncol. (1999) 17:2446-2453.
   PubMed Web of Science ®Google Scholar
• MCCARTHY GM, AWDE JD, GHANDI H, VINCENT M, KOCHA WI: Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol. (1998) 34:484-490.
   PubMed Web of Science ®Google Scholar
• DODD MJ, MIASKOWSKI C, SHIBA GH et al.: Risk factors for chemotherapy-induced oral mucositis: dental appliances, oral hygiene, previous oral lesions and history of smoking. Cancer Invest. (1999) 17:278-284.
   PubMed Web of Science ®Google Scholar
• BOROWSKI B, BENHAMOU E, PICO J, LAPLANCHE A, MARGAINAUD J, HAYAT M: Prevention of oral mucositis in patients treated with high dose chemotherapy and bone marrow transplantation: a randomized controlled trial comparing two protocols of dental care. Oral Oncol. (1994) 30:93-97.
   Google Scholar
• WAHLIN YB, GRANSTROM S, PERSSON S, SJOSTROM M: Multivariate study of enterobacteria and Pseudomonas in saliva of patients with acute leukemia. Oral Surg. Oral Med. Oral Pathol. (1991) 72:300-308.
   PubMedGoogle Scholar
• DODD MJ, LARSON PJ, DIBBLE SL et al.: Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol. Nurs. Forum (1996) 23:921-927.
   PubMedGoogle Scholar
• WOO SB, SONIS ST, MONOPOLI MM, SONIS AL: A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer (1993) 72(5):1612-1617.
   PubMed Web of Science ®Google Scholar
• WARDMAN P, FOLKS LK, BENTZEN SM et al.: Influence of plasma glutathione levels on radiation mucositis. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51:460-464.
   PubMed Web of Science ®Google Scholar
• BOWLER RP, ARCAROLI J, ABRAHAM E, PATEL M, CHANG LY, CARPO JD: Evidence for extracellular superoxide dismutase as a mediator of hemorrhage-induced lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) 284:680-687.
   Google Scholar
• BOWLER RP, SHENG H, ENGHILD JJ, PEARLSTEIN RD, WARNER DS, CRAPO JD: A catalytic antioxidant (AEOL-10150) attenuates expression of inflammatory genes in stroke. Free Radic. Biol. Med. (2002) 33:1141-1152.
   PubMed Web of Science ®Google Scholar
• SMITH KR, UYEMINAMI DL, KODAVANTI UP, CRAPO JD, CHANG LY, PINKERTON KE: Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic. Biol. Med. (2002) 33:11-6-14.
   Google Scholar
• SONIS S, PATEL M, GAMMANS R: AEOL-10150, a catalytic antioxidant reduces the incidence and duration of radiation-induced oral mucositis in a hamster. Eur. J. Cancer (2001) 37(Suppl. 6):361.
   Web of Science ®Google Scholar
• ISRAEL RJ, SONIS ST: Topical dehydroascorbic acid (DHA) reduces moderate to severe mucositis in the hamster acute radiation model. Proc. Am. Soc. Clin. Oncol. (2000) – poster presentation, San Francisco, CA, USA.
   PubMedGoogle Scholar
• Inotek Pharmaceuticals Corporation. International Biotechnology Convention & Exhibition. San Francisco, CA, USA (2004).
   Google Scholar
• RxKinetix initiates Phase II trial in oral mucositis. RxKinetix, Inc. press release (2003).
   Google Scholar
• DELAFLOR-WEISS E, BLOMMAERT F, GILL F, MUGGIA FM, KORTES V, DEN-ENGELSE L: Amifostine (WR-2721) protects from bone marrow toxicity of cisplatin and carboplatin without decreasing platinum-DNA aduct formation. NCI EORTC Symposium on New Drugs for Cancer Therapy . Amsterdam, The Netherlands (1994).
   Google Scholar
• SASSE AD, CLARK LG, SASSE EC, CLARK OA: Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. (2006) 64(3):784-791.
   PubMed Web of Science ®Google Scholar
• RAJAPAKSA R, BHATIA S, SWARNAKAR A, KODALI U, GREENBERG PL: Amifostine in combination with cytokines stimulates in vitro hemopoiesis in myelodysplastic syndromes (MDS). Blood (1998) 92(s1):10.
   Google Scholar
• KOULOULIAS VE, KOUVARIS JR, KOKAKIS JD et al.: Impact on cytoprotective efficacy of intrermediate interval between amifostine administration and radiotherapy: a retrospective analysis. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(4):1148-1156.
   PubMed Web of Science ®Google Scholar
• RADES D, FEHLAUER F, BAJROVIC A et al.: Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother. Oncol. (2004) 70(3):261-264.
   PubMed Web of Science ®Google Scholar
• VACHA P, FEHLAURE F, MAHLMANN B et al.: Randomized Phase III trial of postoperative radiochemotherapy ± amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlentherapie und Onkologie (2003) 179(6):385-389.
   PubMed Web of Science ®Google Scholar
• ANNE PR: Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Sem. Oncol. (2002) 29(6 Suppl. 19):80-83.
   PubMed Web of Science ®Google Scholar
• BRIZEL DM, WASSERMAN TH, HENKE M et al.: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. (2000) 46:1105-1108.
   Web of Science ®Google Scholar
• SPENCER A, HROVATH N, GIBSON J et al.: Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. (2005) 35:971-977.
   PubMed Web of Science ®Google Scholar
• NICOLATOU-GALITIS O, SOTIROPOULOU-LONTOU A, VELEGRAKI A et al.: Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncol. (2003) 39(4):397-401.
   PubMed Web of Science ®Google Scholar
• NGUYEN NP, LEVINSON B, DUTTA S et al.: Amifostine and curative intent chemoradiation for compromised cancer patients. Anti-Cancer Res. (2003) 23(2C):1649-1656.
   PubMed Web of Science ®Google Scholar
• BENESCH M, MCDONALD GB, SCHUBERT M, APPELBAUM FR, DEEG HJ: Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Bone Marrow Transplant. (2003) 32(11):1071-1075.
   PubMed Web of Science ®Google Scholar
• THIEBLEMONT C, DUMONTET C, SAAD H et al.: Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. (2002) 30(11):769-775.
   PubMed Web of Science ®Google Scholar
• TSAVARIS N, KOSMAS C, VADIKA M et al.: Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracial and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. J. Pain Symptom Manage. (2004) 26(3):849-854.
   Web of Science ®Google Scholar
• HOSPERS GA, EISENHAUER EA, DE VRIES EG: The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br. J. Cancer (1999) 80:629-638.
   PubMed Web of Science ®Google Scholar
• BUNTZEL J, KUTTNER K, FROHLICH D, GLATZEL M: Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann. Oncology (1998) 9:505-509.
   PubMed Web of Science ®Google Scholar
• KOUKOURAKIS MI: Amifostine: is there evidence of tumor protection? Sem. Oncol. (2003) 30(6 Suppl. 18):18-30.
   PubMed Web of Science ®Google Scholar
• CASSAT DR, FAZENBAKER CA, KIFLE G, BACHY CM: Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57(3):794-802.
   PubMed Web of Science ®Google Scholar
• STOKMAN MA, WACHTERS FM, KOOPMANS P et al.: Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A Phase II study. Anti-Cancer Res. (2004) 24(5B):3263-3267.
   PubMed Web of Science ®Google Scholar
• MENARD C, CAMPHAUSEN K, MUANZA T et al.: Clinical trial of endorectal amifostine for protection in patients with prostate cancer: rationale and early results. Sem. Oncol. (2003) 30(6 suppl 18):63-67.
   PubMed Web of Science ®Google Scholar
• SAVARESE DM, SAVY G, VAHDAT L, WISCHMEYER PE, COREY B: Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat. Rev. (2003) 29:501-513.
   PubMed Web of Science ®Google Scholar
• GARCIA-DE-LORENZO A, ZARAZAGA A, GARCIA-LUNA PP et al.: Clinical evidence for enteral nutritional support with glutamine: a systematic review. Nutrition (2003) 19(9):805-811.
   PubMed Web of Science ®Google Scholar
• PICCIRILLO N, DE MATTEIS S, SORA F et al.: Glutamine parenteral supplementation in stem cell transplant. Bone Marrow Transplant. (2004) 33(4):455.
   PubMed Web of Science ®Google Scholar
• COCKERHAM MD, WEINBERGER BB, LERCHIE SB: Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann. Pharmacother. (2000) 34:300-330.
   PubMed Web of Science ®Google Scholar
• PYTLIK R, BENES P, PATORKOVA M et al.: Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologus transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplant. (2002) 30(12):953-961.
   PubMed Web of Science ®Google Scholar
• PICCIRILLO N, DE MATTEIS S, LAURENTI L et al.: Glutamine-enriched parenteral nutrition after autologous periphereal blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica (2003) 88(2):192-200.
   PubMed Web of Science ®Google Scholar
• DECKER-BAUMANN C, BUHL K, FROHMULLER S et al.: Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastiatic colorectal cancer. Eur. J. Cancer (1999) 35(2):202-207.
   PubMed Web of Science ®Google Scholar
• OKUNO SH, WOODHOUSE CO, LOPRINZI CL et al.: Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am. J. Clin. Oncol. (1999) 22(3):258-261.
   PubMed Web of Science ®Google Scholar
• SCHLOERB PR, SKIKNE BS: Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. J. Parent. Ent. Nutr. (1999) 23(3):117-122.
   PubMed Web of Science ®Google Scholar
• OKUNO SH, WOODHOUSE CO, LOPRINZI CL et al.: Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am. J. Clin. Oncol. (1999) 22:258-261.
   PubMed Web of Science ®Google Scholar
• COUGHLIN DICKSON TM, WONG RM, NEGRIN RS et al.: Effect of oral glutamine supplementation during bone marrow transplantation. J. Parent. Ent. Nutr. (2000) 24:61-66.
   PubMed Web of Science ®Google Scholar
• BLIJLEVENS NM, DONNELLY JP, NABER AH, SCHATTENBERG AV, DEPAUW BE: A randomised double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Supp. Care Cancer (2005) 13(10):790-796.
   PubMed Web of Science ®Google Scholar
• AQUINO E, HARVEY AR, GARVIN JH et al.: A double-blind randomized placebo-controlled study of oral glutamine n the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. (2005) 36(7):611-616.
   PubMed Web of Science ®Google Scholar
• HWANG JM, CHAN DC, CHANG TM et al.: Effects of oral arginine and glutamine on radiation-induced injury in the rat. J. Surg. Res. (2003) 109:149-154.
   PubMed Web of Science ®Google Scholar
• ANDERSON PM, RAMSEY NKC, SHU XO et al.: Effect of low- dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant. (1998) 22:339-344.
   PubMed Web of Science ®Google Scholar
• HUANG EY, LEUNG SW, WANG CJ et al.: Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (2000) 46(3):535-539.
   PubMed Web of Science ®Google Scholar
• Summary of the American Society of Clinical Oncology meeting (2002). Orlando, FL, USA. GCroadsdell IDdb meeting report (2002).
   Google Scholar
• PETERSON DE: Phase III study: AES:14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2004) 22:2917.
   Google Scholar
• OSAKI T, UETA E, YONEDA K, HIROTA J, YAMIMOTO T: Prophylaxis of oral mucositis associated with chemoradiotherpay for oral carcinoma by Azelastine hydrochloride with other antioxidants. Head Neck (1994) 16:331-339.
   PubMed Web of Science ®Google Scholar
• KNICK VB, BRAMSON N, DAVIS ST et al.: Novel substituted oxindole inhibitors of cyclin dependant kinases arrest affecting CDK 1, 2 and 6 and protect normal cells from chemotherapy induced toxicity in vitro. Proc. Am. Assoc. Cancer Res. (2000) 41 – poster presentation, San Francisco, CA, USA.
   Google Scholar
• TANG J, SHEWCHUK LM, SATO H, HASEGAWA M, WASHIO Y, NISHIGAKI N: Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation and X-ray crystallographic analysis. Bioorg. Med. Chem. Lett. (2003) 13(18):2985-2988.
   PubMed Web of Science ®Google Scholar
• 449203: DAVIS ST, GRIFFIN R, KNICK V et al.: Prevention of CT-induced alopecia by GW-420371X, a small molecule inhibitor of DCK2 ser/thr kinase. Proc. Am. Assoc. Cancer Res. (2002) – poster presentation, San Francisco, CA, USA.
   Google Scholar
• DAVIS ST, BRAMSON N, DICKERSON S, DOLD KM et al.: Novel cyclin dependant kinase inhibitors prevent chemotherapy-induced alopecia. Proc. Am. Assoc. Cancer Res. (2000) 41 – poster presentation, San Francisco, CA, USA.
   Google Scholar
• DUENAS-GONZALEZ A, SOBREVILLA-CALVO P, FRIAS-MENDIVIL M et al.: Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant. (1996) 17:809-812.
   PubMed Web of Science ®Google Scholar
• PASSALI D, VONONTE M, PASSALI GC et al.: Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study. Clin. Therapeutics (2001) 23(9):1508-1518.
   PubMed Web of Science ®Google Scholar
• PULLE C, STURLESE E: Clinical trial comparing the activity and efficacy of ibuprofen isobutanolammonium versus benzydamnie hydrochloride, applied as vaginal irrigations, in patients with vaginitis. Clin. Exp. Obst. Gynecol. (2002) 29(3):173-179.
   PubMed Web of Science ®Google Scholar
• STOKMAN MA, SPIJKERVET FKL, BURLAGE FR, ROODENBURG JLN: Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study. Supp. Care Cancer (2005) 13:42-48.
   PubMed Web of Science ®Google Scholar
• LEBORGNE JH, LEBORGNE F, ZUBIZARRETA E, ORTEGA B, MEZZERA J: Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother. Oncol. (1998) 47:145-148.
   PubMed Web of Science ®Google Scholar
• CLIFT RA, BIANCO JA, APPELBAUM FR et al.: A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood (1993) 82:2025-2030.
   PubMed Web of Science ®Google Scholar
• ATTAL M, HUGUET F, RUBIE H et al.: Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood (1993) 82:732-736.
   PubMed Web of Science ®Google Scholar
• STOCKSCHLADER M, KALHS P, PETERS S et al.: Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. (1994) 13:203-207.
   PubMed Web of Science ®Google Scholar
• FERRA C, DE SANJOSE S, LASTRA CD et al.: Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant. (1997) 20:1075-1080.
   PubMed Web of Science ®Google Scholar
• Research & Development: compound ATL-101. Alizyme plc Company World Wide Website (2001).
   Google Scholar
• Drug development pipeline: ATL-101, AZM-090, AZM-145. Alizyme plc Company Communicaton (2003).
   Google Scholar
• Successful completion of Phase Ib clinical rial and notice of grant of a European patient for atl-104 in mucositis. Alizyme plc press release (2002).
   Google Scholar
• Alizyme granted CTX for Phase IIa clinical trial for ATL-104 for mucositis. Alizyme plc press release (2003).
   Google Scholar
• BINNIE WH, CURRO FA, KHANDWALA A, VAN INWEGAN RG: Amelxanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend. Contin. Educ. Dent. (1997) 18:1116-1118,1120-1122.
   PubMedGoogle Scholar
• KHANDWALA A, VAN INWEGEN RG, ALFANO MC: 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. clinical demonstration of acceleration of healing and resolution of pain. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (1997) 83:222-230.
   PubMed Web of Science ®Google Scholar
• Product programs: Tehcnology portfolio. Access Pharmaceuticals, Inc. Company World Wide Website (2003).
   Google Scholar
• Access announces positive Phase II mucositis trial outcome; technology may have significant potential for management of mucositis. Access Pharmaceuticals, Inc. press releases (2001).
   Google Scholar
• Access reports positive results of preclinical studies in oral mucositis. Access Pharmaceuticals, Inc. press release (2002).
   Google Scholar
• RIBOLDI E, FRASCAROLI G, TRANSIDICO P et al.: Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists. Br. J. Pharmacol. (2003) 140(2):377-383.
   PubMed Web of Science ®Google Scholar
• PILLONI AP, BUTTINI G, GIANNARELLI D et al.: Antimcrobial action of Nitens mouthwash (cetyltrimethylammonium narpoxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor. Chemotherapy (2002) 48(4):168-173.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, STEVESON-MOORE P, JACKSON S, MOHAMED JH, SPINELLI JJ: Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int. J. Radiat. Oncol. Biol. Phys. (1989) 16:1571-1575.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, SILVERMAN S JR, PAGGIARINO DA et al.: Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer (2001) 92:875-885.
   PubMed Web of Science ®Google Scholar
• KATI I, TEKIN M, SILARY E, HUSEYINOGLU UA, YILDIZ H: Does benzydamine hydrochloride applied pre-emptively reduce sore throat due to laryngeal mask airway? Anesth. Analg. (2004) 99(3):710-712.
   PubMed Web of Science ®Google Scholar
• CHENG KK, CHANG AM: Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nurs. (2003) 26(6):476-484.
   PubMed Web of Science ®Google Scholar
• CHENG KK. Children’s acceptance and tolerance of chlorhexidine and benzydamine oral rinse in the treatment of chemotherapy-induced oropharyngeal mucositis. Eur. J. Oncol. Nurs. (200) 8(4):341-349.
   PubMed Web of Science ®Google Scholar
• FUJISAWA K, MIYAMOTO Y, NAGAYAMA M: Basic fibroblast growth factor and epidermal growth factor reverse impaired ulcer healing of the rabbit oral mucosa. J. Oral Pathol. Med. (2003) 32:358-366.
   PubMed Web of Science ®Google Scholar
• NAKASE H, PETERSON J, BENDELE A, HENRI L, SARTOR RB: GFG-20 prevents and treats T-cell-mediated colitis by promoting epithelial restitution and stimulating immunosuppressive pathways. Gastroenterol. (2003) 124(Suppl. 1).
   Google Scholar
• ODA Y, KAGAMI H, UEDA M: Accelerating effects of basic fibroblast growth factor on wound healing of rat palatal mucosa. J. Oral Maxillofac. Surg. (2004) 62:73-80.
   PubMed Web of Science ®Google Scholar
• JEFFERS M, MCDONALD EF, CHILLAKURU RA et al.: A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterol. (2002) 123:1151-1162.
   PubMed Web of Science ®Google Scholar
• JEFFERS M, MCDONALD WF, CHILLAKURU RA, SHIMKETS RA, BENDELE AM, LICHENSTEIN HS: A novel human growth factor, FGF-20 is active in animal models of inflammatory bowel disease. Gastroenterol. (2002) 122(Suppl. 1).
   Google Scholar
• ALVAREZ E, FEY EG, VALAX P et al.: Preclinical characterization of CG-53135(FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin. Cancer Res. (2003) 9:3454-3461.
   PubMed Web of Science ®Google Scholar
• ALVEREZ E, JEFFERS MA, VALAZ P et al.: Adminstration of CG-53135 (FGF-20) ameliorates radiation and chemotherapy-induced oral mucositis in hamsters. Proc. Am. Assoc. Cancer Res. (2003) 44 – poster presentation, San Francisco, CA, USA.
   Google Scholar
• Curagen presents new preclinical data on CG-53135 for oral mucositis. CuragGen Corp. press release (2004).
   Google Scholar
• CuraGen details clinical development plan for CG53135 and CR002. Rodman&Renshaw 6th Annual Healthcare Conference. CuraGen Corp. press release (2004).
   Google Scholar
• DORR W: Modulation of repopulation processes in oral mucosa: experimental results. Int. J. Radiat. Biol. (2003) 79:53-57.
   PubMed Web of Science ®Google Scholar
• FLANDERS KC, BURMESTER JK: Medical applications of transforming growth factor-β. Clin. Med. Res. (2003) 1(1):13-20.
   PubMedGoogle Scholar
• WYMENGA AN, VAN DER GRAAF WT, HOFSTRA LS et al.: Phase I study of transforming growth factor-β3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin. Cancer Res. (1999) 5(6):1363-1368.
   PubMed Web of Science ®Google Scholar
• FONCUBERTA MC, CAGNONI PJ, BRANDTS CH et al.: Topical transforming growth factor-β3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J. Immunother. (2001) 24:384-388.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, EMERTON S, GUGLIETTA A, LE N: Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol. (1997) 33:359-363.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, GORSKY M, GUGLIETTA A, LE N, SONIS ST: The correlation between epidermal growth factor levels in saliva and severity of oral mucositis during oropharyngeal radiation therapy. Cancer (2000) 89:2258-2265.
   PubMed Web of Science ®Google Scholar
• GIRDLER NM, MCGURK M, AQUAL S, PRINCE M: The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration. A Phase I clinical trial. Am. J. Clin. Oncol. (1995) 18:403-406.
   PubMed Web of Science ®Google Scholar
• CHI K-H, CHEN, C-H, CHAN W-K et al.: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherpy. J. Clin. Oncol. (1995) 13:2620-2628.
   PubMed Web of Science ®Google Scholar
• KANNAN V, BAPSY PP, ANANTHA H et al.: Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int. J. Radiat. Oncol. Biol. Phys. (1997) 37:1005-1010.
   PubMed Web of Science ®Google Scholar
• ROSSO M, BLASI G, GHRELONE E, ROSSO R: Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy. J. Chemother. (1997) 9:382-385.
   PubMed Web of Science ®Google Scholar
• WAGNER W, ALFRINK M, HAUS U, MATT J: Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Anti-Cancer Res. (1999) 19:799-803.
   PubMed Web of Science ®Google Scholar
• SAARILAHTI K, KAJANTI M, JOENSUU T, KOURI M, JOENSUU H: Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized Phase III study. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54(2):479-485.
   PubMed Web of Science ®Google Scholar
• MASCARIN M, FRANCHIN G, MINATEL E et al.: The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol. (1999) 35:203-208.
   PubMed Web of Science ®Google Scholar
• KARTHAUS M, ROSENTHAL C, HUEBNER G et al.: Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant. (1998) 22:781-785.
   PubMed Web of Science ®Google Scholar
• BEZ C, DEMAROSI F, SARDELLA A et al.: GM-CSF mouthrinses in the treatment of severe oral mucositis: a pilot study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (1999) 88:311-315.
   PubMed Web of Science ®Google Scholar
• IBRAHIM EM, AL-MULHIM FA: Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Med. Oncol. (1997) 14:47-51.
   PubMed Web of Science ®Google Scholar
• CARTEE L, PETROS WP, ROSNER GL et al.: Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine (1995) 7:471-477.
   PubMed Web of Science ®Google Scholar
• NICOLATOU O, SOTIROPOULOU-LONTOU A, SKARLATOS J et al.: A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:551-556.
   PubMed Web of Science ®Google Scholar
• MASUCCI B, BROMAN P, KELLY C et al.: Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with roal and oropharynx tumors treated ith curative radiotherapy: a multicenter open randomized Phase III study. Med. Oncol. (2005) 22(3):247-256.
   PubMed Web of Science ®Google Scholar
• Drug development pipeline. Veldona® Amarillo Biosciences, Inc. Company Communication (2002).
   Google Scholar
• Drug development pipeline: interleukin-4 receptor, Immunex, interleukin-15, Immunex, Flt-3 ligand, Immunex, TNF-α protease inhibitors. Immunex Corp. Company Communication (1995).
   Google Scholar
• Products in preclinical development. Immunex Corp. Company World Wide Website (1996).
   Google Scholar
• Form 10-K, Immunex Corp. Securities and Exchange Commission (2000).
   Google Scholar
• KUNIYASU H, OHMORI H, SASAKI T et al.: Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin.Cancer Res. (2003) 9(13):4802-4810.
   PubMed Web of Science ®Google Scholar
• Metron. Derivatives of the family of HGF cytokines. Dompe Group Company World Wide Website (2000).
   Google Scholar
• Dompe Group-corporate profile. Dompe Group Company World Wide Website (2004).
   Google Scholar
• DANILENKO DM: Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol. Pathol. (1999) 27:64-71.
   PubMed Web of Science ®Google Scholar
• Growth factor receptors-SRI conference. Philadelphia, PA, USA. Lowman H IDDB Meeting Report (2003).
   Google Scholar
• LU JZ, CHOW G, SCULLY S, FARRELL C, LACEY DL: Keratinocyte growth factor (KGF) ameliorates salivary gland function in rat models of irradiation injury. Proc. Am. Assoc. Cancer Res. (2002) – poster presentation, San Francisco, CA, USA.
   Google Scholar
• HILLE A, RAVE-FRANK M, PRADIER O et al.: Effect of keratinocyte growth factor on the proliferation, clonigenic capacity and colony size of human epithelial tumor cells in vitro. Int. J. Radiat. Biol. (2003) 79:119-128.
   PubMed Web of Science ®Google Scholar
• FARRELL CL, REX KL, KAUFMAN SA et al.: Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int. J. Radiat. Biol. (1999) 75:609-620.
   PubMed Web of Science ®Google Scholar
• FARRELL CL, BREADY JV, REX KL et al.: Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. (1998) 58:933-939.
   PubMed Web of Science ®Google Scholar
• MEROPOL NJ, SOMER, RA, GUTHEIL J et al.: Randomized Phase I trial of recombinant human heratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J. Clin. Oncol. (2003) 21:1452-1458.
   PubMed Web of Science ®Google Scholar
• SPIELBERGER RT, STIFF P, EMMANOUILIDES C et al.: Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a Phase II trial. Proc. Am. Soc. Clin. Oncol. (2001) 20:7a (abstract 25).
   Web of Science ®Google Scholar
• American Society for Therapeutic Radiology and Oncology (Part II) – 44th annual Meeting. New Orleans, LA, USA. SJ Chmura IDDB meeting report (2002).
   Google Scholar
• Amgen announces positive results of Phase III study for rHu-KGF. Amgen, Inc. press release (2003).
   Google Scholar
• DORR W, NOACK R, SPEKL K, FARRELL CL: Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int. J. Radiat. Biol. (2001) 77:341-347.
   PubMed Web of Science ®Google Scholar
• DORR W, SPEKL K, FARRELL CL: The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif. (2002) 35(Suppl. 1):86-92.
   PubMed Web of Science ®Google Scholar
• ODA Y, KAGAMI H, UEDA M: Accelerating effects of basic fibroblast growth factor on wound healing of rat palatal mucosa. J. Oral Maxillofac. Surg. (2004) 62:73-80.
   PubMed Web of Science ®Google Scholar
• Results of Phase II repifermin clinical trial demonstrate safety and efficacy in patients with cancer therapy-induced mucositis. Human Genome Sciences, Inc. press release (2003).
   Google Scholar
• Human Genome Sciences reports results of Phase II clinical trial of repifermin in paitents with cancer therapy-induced mucositis. Human genome Sciences, Inc. press release (2004).
   Google Scholar
• Human Genome Sciences reports results of clinical trial of repifermin in patients with chronic venous ulcers. Human genome Sciences, Inc. press release (2003).
   Google Scholar
• SANDBORN WJ, SANDS BE, WOLF DC et al.: Repifermin (keratinocyte growth factor 2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Gastroenterol. (2002) 122(Suppl. 1).
   Google Scholar
• Immunex pipeline: Sargramostim. Immunex Crop Company Communication (2001).
   Google Scholar
• PRINCE HM, REGESTER G, GATES P et al.: A Phase Ib clinical trial of P701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy. Biol. Blood Marrow Transplant. (2005) 11:512-520.
   PubMed Web of Science ®Google Scholar
• GroPep announces positive Phase Ib clinical trial results for oral mucositis product (PV701). GroPep Ltd press release (2003).
   Google Scholar
• EPSTEIN JB, RANSIER A, SHERLOCK CH, SPINELLI JJ, REECE D: Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Oral Oncol. Eur. J. Cancer (1996) 32(B):158-162.
   Google Scholar
• WARKENTIN DI, EPSTEIN JB, CAMPBELL LM et al.: Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. Ann. Pharmacother. (2002) 36:1525-1531.
   PubMed Web of Science ®Google Scholar
• DONNELLY JP, MUUS P, HORREVORTS AM, SAUERWEIN RW, DE PAUW BE: Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. Scan. J. Infect. Dis. (1993) 25(1):43-50.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, RANSIER A, LUNN R et al.: Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg. Oral Med. Oral Pathol. Oral. Radiol. Endod. (1996) 81:291-296.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, FREILICH MM, LE ND: Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg. Oral Med. Oral Pathol. (1993) 76:69-74.
   Google Scholar
• SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J. Infect. Dis. (1995) 171(6):1545-1552.
   PubMed Web of Science ®Google Scholar
• SAMARANAYAKE LP, ROBERTSON AG, MACFARLANE TW, HUNTER IP, SOUTAR DS, FERGUSON MM: The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clin. Radiol. (1998) 39:291-294.
   Google Scholar
• EPSTEIN JB, VICKERS L, SPINELLI J, REECE D: Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg. Oral Med. Oral Pathol. (1992) 73:692-699.
   Google Scholar
• DODD MJ, LARSON PJ, DIBBLE SL et al.: Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol. Nurs. Forum (1996) 23:921-927.
   PubMedGoogle Scholar
• FOOTE RL, LOPRINZI CL, FRANK AR et al.: Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J. Clin. Oncol. (1994) 12:2630-2633.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, LOH R, STEVENSON-MOORE P, MCBRIDE B, SPINELLI J: Chlorhexidine rinse in prevention of dental caries in patients following radiation therapy. Oral Surg. Oral Med. Oral Pathol. (1989) 68:401-405.
   PubMedGoogle Scholar
• EPSTEIN JB, MCBRIDE BC, STEVENSON-MOORE P, MERILEES H, SPINELLI J: The efficacy of chlrohexidine gel in reductions of Streptococcus mutans and lactobaccilus species in patients treated with radiation therapy. Oral Surg. Oral Med. Oral Pathol. (1991) 71:172-178.
   PubMedGoogle Scholar
• EPSTEIN JB, RANSIER A, LUNN R, SPINELLI J: Enhancing the effect of oral hygiene with use of a foam brush with chlorhexidine. Oral Surg. Oral Med. Oral Pathol. (1994) 77:242-247.
   PubMedGoogle Scholar
• RANSIER A, EPSTEIN JB, KAUFFMAN E, GORSKY M: Use of chlorhexidine oral rinse in patients receiving hematopoietic cell transplants. J. Appl. Res. Clin. Dent. (2004) 1:1-6.
   Google Scholar
• EPSTEIN JB, TRUELOVE EL, HANSON-HUGGINS K et al.: Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Supp. Care Cancer (2004) 12(7):517-525.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, GORSKY M, CALDWELL J: Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg. Oral Med. Oral Pathol. Oral. Radiol. Endod. (2002) 93:671-675.
   PubMed Web of Science ®Google Scholar
• RAHN R, ADAMIETZ IA, BOETTCHER HD, SCHAEFER V, REIMER K, FLEISCHER W: Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatol. (1997) 195:57-61.
   PubMedGoogle Scholar
• LEVY-POLLACK MP, SEBELLI P, POLACK NL: Incidence of oral complications and application of a preventive protocol in children with acute leukemia. Spec. Care Dentistry (1998) 18:189-193.
   PubMedGoogle Scholar
• OKUNO SH, FOOTE RL, LOPRINZI CL et al.: A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer (1997) 79:2193-2199.
   PubMed Web of Science ®Google Scholar
• SYMONDS RP, MCILROY P, KHORRAMI J et al.: The reduction of readiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br. J. Cancer (1996) 74:312-317.
   PubMed Web of Science ®Google Scholar
• EL-SAYED S, BABID A, SHELLEY W et al.: Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, Phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J. Clin. Oncol. (2002) 20:3956-3963.
   PubMed Web of Science ®Google Scholar
• BELLM L, LEHRER RI, GANZ T: Protegrins: new antibiotics of mammalian origin. Expert Opin. Investig. Drugs (2000) 9:1731-1742.
   PubMed Web of Science ®Google Scholar
• LOURY D, EMBREE JR, STEINBERG DA, SONIS ST, FIDDES JC: Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (1999) 87:544-551.
   PubMed Web of Science ®Google Scholar
• GILES FJ, MILLER CB, HURD DD et al.: A Phase III, randomized, double-blind, placebo-controlled, multinational trial of sieganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk. Lymphoma (2003) 44(7):1165-1172.
   PubMed Web of Science ®Google Scholar
• VESOLE DH, FUCHS HJ: IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy. Blood (1999) 94(Suppl. 1):10.
   Google Scholar
• CELLA D, PULLIAM J, FUCHS H et al.: Evaluation of pain associated with oral mucositis during the acute period after administration of high-does chemotherapy. Cancer (2003) 98(2):406-412.
   PubMed Web of Science ®Google Scholar
• GILES FJ, RODRIGUEZ R, WEISDORF D et al.: A Phase III, randomized, double-blind, placebo-controlled, study of Iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Res. (2004) 28(6):559-565.
   PubMed Web of Science ®Google Scholar
• TROTTI A, GARDEN A, WARDE P et al.: A multinational randomized Phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):674-681.
   PubMed Web of Science ®Google Scholar
• GILES FJ, HURD DD, RODRIGUEZ R et al.: A Phase III, randomized, placebo-controlled, double-blind, multicenter study (RPCDBM) of Iseganan HCL oral solution (Iseganan) in reducing severity of oral mucositis in patients receiving stomatotoxic chemotherapy. Blood (2002) 100:11.
   PubMed Web of Science ®Google Scholar
• TROTTI A, GARDEN AS, WARDE P et al.: Phase III trial of Iseganan HCl oral solution (Iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). Proc. Am. Soc. Clin. Oncol. (2002) – poster presentation, San Francisco, CA, USA.
   Google Scholar
• ROTHSTEIN DM, HELMERHORST EJ, SPACCIAPOLI P, OPPENHEIM FG, FRIDEN P: Histatin-derived peptides: potential agents to treat localised infections. Expert Opin. Investig. Drugs (2002) 1:47-59.
   Google Scholar
• PAQUETTE DW, SIMPSON DM, FRIDEN PM, BRAMAN V, WILLIAMS RC: Safety and clinical effects of topical histatin gels in humans with experimental gingivitis. J. Clin. Periodontol. (2002) 29:1051-1058.
   PubMed Web of Science ®Google Scholar
• 443619: Better Medicines: prevention and treatment of common infectious diseases. BAXRSMI Conference – Superbugs and Superdrugs – Innovation in Anti-Infectives. London, UK (2002).
   Google Scholar
• CORNER AM, BRIGHTMAN VJ, COOPER S, YANKELL SL, MALAMUD D: Clinical study of a C331G containing mouthrinse: effect on salivary microorganisms. J. Clin. Dent. (1990) 2:34-38.
   PubMedGoogle Scholar
• RENTON-HARPER P, ADDY M, MORAN J, DOHERTY FM, NECOMBE RG: A comparison of chlorhexidine, cetylpyridinium chloride, triclosan, and C31G mouthrinse products for plaque inhibition. J. Periodontol. (1996) 67:486-489.
   PubMed Web of Science ®Google Scholar
• KREBS FC, MILLER SR, MALAMUD D, HOWETT MK, WIGDAHL B: Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulphate, sodium dodecyl sulphate. Antiviral Res. (1999) 43(3):157-173.
   PubMed Web of Science ®Google Scholar
• Orapharma completes preclinical development on its oral mucositis program. OraPharma, Inc. press release (2000).
   Google Scholar
• OraPharma reports favourable results from Phase I trial of OC-1012 for mucositis. OraPharma, Inc. press release (2002).
   Google Scholar
• MAHOOD DJ, DOSE AM, LOPRINZI CL et al.: Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J. Clin. Oncol. (1991) 9:449-452.
   PubMed Web of Science ®Google Scholar
• CASCINU S, FEDELI A, FEDELI SL, CATALANO G: Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur. J. Cancer B. Oral Oncol. (1994) 30B:234-236.
   PubMed Web of Science ®Google Scholar
• BAYDER M, DIKILITAS M, SEVINC A, AYDOGDU I: Prevention of oral mucositis due to 5-fluorouracil treatment with oral cyrotherapy. J. Nation. Med. Assoc. (2005) 97(8):1161-1164.
   PubMed Web of Science ®Google Scholar
• NIKOLTEEI S, HUDE S, SHAW T, MYERS H, KRISTJANSON LJ: Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5-fluorouracil. J. Clin. Nurs. (2005) 14(6):750-753.
   PubMed Web of Science ®Google Scholar
• KARAGOZUGLU S, FIOLILZ ULUSOY M: Chemotherapy: the effect of oral cryotherapy on the development of mucositis. J. Clin. Nurs. (2005) 14(6):754-765.
   PubMed Web of Science ®Google Scholar
• AISA Y, MORI T, KUDO M et al.: Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Supp. Care Cancer (2005) 13(4):266-269.
   PubMed Web of Science ®Google Scholar
• AHMED T, ENGELKING C, SZALYGA J et al.: Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant. (1993) 12(2):131-132.
   PubMed Web of Science ®Google Scholar
• OBLON DJ, PAUL SR, OBLON MB, MALIK S: Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant. (1997) 20:961-963.
   PubMed Web of Science ®Google Scholar
• ProCertus products. ProCertus BioPharm, Inc. Company World Wide Website (2002).
   Google Scholar
• FIDLER P, LOPRINZI CL, O’FALLON JR et al.: Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer (1996) 77:522-525.
   PubMed Web of Science ®Google Scholar
• COWEN D, TARDIEU C, SCHUBERT M et al.: Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (1997) 38(4):697-703.
   PubMed Web of Science ®Google Scholar
• BARASCH A, PETERSON DE, TANZER JM et al.: Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer (1995) 76(12):2550-2556.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, WONG FL: The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (1994) 28(3):693-698.
   PubMed Web of Science ®Google Scholar
• MAKKONEN TA, BOSTROM P, VILJA P, JOENSUU H: Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int. J. Radiat. Oncol. Biol. Phys. (1994) 30:177-182.
   PubMed Web of Science ®Google Scholar
• MERIDITH R, SALTER M, KIM R et al.: Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (1997) 37:275-279.
   PubMed Web of Science ®Google Scholar
• LEVEQUE FG, PARZUCHOWSKI JB, FARINACCI GC et al.: Clinical evaluation of MGI 209, an anesthetic film-forming agent for relief from painful oral ulcers associated with chemotherapy. J. Clin. Oncol. (1992) 10:1963-1968.
   PubMed Web of Science ®Google Scholar
• INNOCENTI M, MOSCATELLI G, LOPEZ S: Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J. Pain Symptom Manage. (2002) 24(5):456-457.
   PubMed Web of Science ®Google Scholar
• BUCHSEL PC: Gelclair oral gel. Clin. J. Oncol. Nurs. (2003) 7(1):109-110.
   PubMedGoogle Scholar
• EPSTEIN JB, TRUELOVE EL, OIEN H, ALLISON C, LE ND, EPSTEIN MS: Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. Oral Oncol. (2001) 37:632-637.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, TRUELOVE EL, OIEN H, LE ND, EPSTEIN MS: Oral topical doxepin rinse: anesthetic effect in normal subjects. Pain Res. Manage. (2003) 8:195-197.
   PubMedGoogle Scholar
• CERCHIETTI LCA, NAVIGANTE AH, BONOMI MR et al.: Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer (2002) 25:2230-2236.
   Google Scholar
• CERCHIETTI LCA, NAVIGANTE AH, KORTE MW et al.: Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain (2003) 10:265-273.
   Google Scholar
• GALLAGHER R: Methadone mouthwash for the management of oral ulcer pain. J. Pain Symptom Manage. (2004) 27:390-391.
   PubMedGoogle Scholar
• EpiCept Crop. International Biotechnology Convention and Exhibition. Toronto, ON, Canada (2002) Suppl.
   Google Scholar
• EpiCept Products Company World Wide Website (2003).
   Google Scholar
• RUBENSTEIN EB, PETERSON DE, SCHUBERT M et al.: Mucositis study section of the Multinational Association for Supportive Care in Cancer. International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer (2004) 100(Suppl. 1):2026-2046.
   PubMed Web of Science ®Google Scholar